Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (451-460 of 910) with videos related to

Pageof 91
Sort By:
Open Heart|May 11, 2023
Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysisLinda P T Joosten, Rosanne van Maanen, Carline J van den Dries, et al.
Journal of the American College of Cardiology|July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke DatabankG Michael Felker, Larry A Allen, Stuart J Pocock, et al.
American Heart Journal|September 29, 2014
Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary interventionAkshay Bagai, Phillip J Schulte, Christopher B Granger, et al.
American Heart Journal|April 29, 2006
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialJohn J V McMurray, James B Young, Mark E Dunlap, et al.
The New England Journal of Medicine|March 16, 2006
Comparison of fondaparinux and enoxaparin in acute coronary syndromes, Salim Yusuf, Shamir R Mehta, et al.
Circulation. Cardiovascular Interventions|September 23, 2010
A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction TrialAmanda Stebbins, Rajendra H Mehta, Paul W Armstrong, et al.
JAMA|October 13, 2005
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureCatherine Demers, John J V McMurray, Karl Swedberg, et al.
European Heart Journal|September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeStuart J Pocock, John J V McMurray, Joanna Dobson, et al.
Journal of the American College of Cardiology|December 6, 2008
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) ProgramPeter A Meredith, Jan Ostergren, Inder Anand, et al.
Clinical Trials (London, England)|June 16, 2023
Pragmatic guidance for embedding pragmatic clinical trials in health plans: Large simple trials aren't so simpleNoelle M Cocoros, Jerry H Gurwitz, Mark J Cziraky, et al.
Pageof 91

Showing results (451-460 of 910) with videos related to

Sort By:
Pageof 91
Open Heart|May 11, 2023
Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysisLinda P T Joosten, Rosanne van Maanen, Carline J van den Dries, et al.
Journal of the American College of Cardiology|July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke DatabankG Michael Felker, Larry A Allen, Stuart J Pocock, et al.
American Heart Journal|September 29, 2014
Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary interventionAkshay Bagai, Phillip J Schulte, Christopher B Granger, et al.
American Heart Journal|April 29, 2006
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialJohn J V McMurray, James B Young, Mark E Dunlap, et al.
The New England Journal of Medicine|March 16, 2006
Comparison of fondaparinux and enoxaparin in acute coronary syndromes, Salim Yusuf, Shamir R Mehta, et al.
Circulation. Cardiovascular Interventions|September 23, 2010
A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction TrialAmanda Stebbins, Rajendra H Mehta, Paul W Armstrong, et al.
JAMA|October 13, 2005
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureCatherine Demers, John J V McMurray, Karl Swedberg, et al.
European Heart Journal|September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeStuart J Pocock, John J V McMurray, Joanna Dobson, et al.
Journal of the American College of Cardiology|December 6, 2008
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) ProgramPeter A Meredith, Jan Ostergren, Inder Anand, et al.
Clinical Trials (London, England)|June 16, 2023
Pragmatic guidance for embedding pragmatic clinical trials in health plans: Large simple trials aren't so simpleNoelle M Cocoros, Jerry H Gurwitz, Mark J Cziraky, et al.
Pageof 91